Why Biden's strategy to prepare U.S. for future pandemics is 'underwhelming'
Earlier this month, the White House unveiled a new strategy aimed at preparing for future pandemics. The plan costs $65 billion over the next 10 years, and allocates a significant portion of those funds to developing technology that can quickly produce vaccines, antiviral drugs, and diagnostic tests.
It sounds like a promising start, but some experts aren't all that excited about it. "It's underwhelming," Mike Osterholm, an epidemiologist at the University of Minnesota, told The Atlantic's Ed Yong. "That $65 billion should have been a down payment, not the entire program. It's a rounding error for our federal budget, and yet our entire existence going forward depends on this."
Meanwhile, Alexandra Phelan, an expert on international law and global health policy at Georgetown University, told Yong that it's the way the funds are distributed that's concerning. "We're so focused on these high-tech solutions because they appear to be what a high-income country would do," she said.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Instead, Yong writes, there's a case to be made that turning America's public health sector into a much more robust operation is just as essential as gearing up to produce vaccines. That means giving communities more money to hire and train more workers and improve their workplace infrastructure; it's not enough to simply react to emergencies in the future. Finally, there likely needs to be a greater effort to address the issues that make certain communities more vulnerable to public health crises than others — that could include increased paid sick leave, safe public housing, and food assistance, Yong writes.
For what it's worth, Eric Lander, the director of the Office of Science and Technology Policy and Biden's science adviser, agrees that the $65 billion plan isn't enough. "Nobody should read that plan as the limit of what needs to be done," he told Yong. "I have no disagreement that a major effort and very substantial funding are needed." Read more at The Atlantic.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.
-
Decrepit train stations across the US are being revitalized
Under the Radar These buildings function as hotels, restaurants and even museums
By Justin Klawans, The Week US Published
-
Crossword: January 30, 2025
The Week's daily crossword
By The Week Staff Published
-
Sudoku medium: January 30, 2025
The Week's daily medium sudoku puzzle
By The Week Staff Published
-
Study finds possible alternative abortion pill
Speed Read An emergency contraception (morning-after) pill called Ella could be an alternative to mifepristone for abortions
By Peter Weber, The Week US Published
-
America is leaving WHO. What does that mean for public health?
Today's Big Question Trump orders the withdrawal
By Joel Mathis, The Week US Published
-
Is this the end of cigarettes?
Today's Big Question An FDA rule targets nicotine addiction
By Joel Mathis, The Week US Published
-
How close are we to a norovirus vaccine?
Today's Big Question A new Moderna trial raises hopes of vanquishing a stomach bug that sickens millions a year
By David Faris Published
-
Kidney stones are affecting children far more than they once did
Under the radar Salt may be to blame
By Devika Rao, The Week US Published
-
HMPV is spreading in China but there's no need to worry
The Explainer Respiratory illness is common in winter
By Devika Rao, The Week US Published
-
Walking pneumonia cases are picking up pace
The explainer Another respiratory illness to be wary of
By Devika Rao, The Week US Published
-
Marty Makary: the medical contrarian who will lead the FDA
In the Spotlight What Johns Hopkins surgeon and commentator Marty Makary will bring to the FDA
By David Faris Published